سعر ابيكوتيل 20مجم 3 فيال 2024

Epicotil (tenoxicam) 20 mg lyophilized powder for IM/IV injection, box of 3 vials, EIPICO; oxicam NSAID.

• Symptomatic treatment of rheumatoid arthritis, osteoarthritis, arthrosis and ankylosing spondylitis.Population: AdultsMedsafe (New Zealand Medicines and Medical Devices Safety Authority)
• Extra-articular musculoskeletal disorders and post-operative pain.Population: AdultsMedsafe (New Zealand Medicines and Medical Devices Safety Authority)

• Gastrointestinal effects are most common (nausea, vomiting, diarrhoea, dyspepsia, abdominal pain, peptic ulcer, bleeding); hypersensitivity reactions and blood disorders have been reported; local tolerance of injection is good.International label, same formulation · Medsafe (New Zealand Medicines and Medical Devices Safety Authority)

• Hypersensitivity to tenoxicam or other NSAIDs (including NSAID-induced asthma, rhinitis, urticaria or angioedema); history of GI bleeding or peptic ulcer; haemorrhagic diathesis; severe heart, renal or hepatic failure; third trimester of pregnancy.International label, same formulation · Medsafe (New Zealand Medicines and Medical Devices Safety Authority)

• Avoid concomitant NSAIDs including COX-2 inhibitors; use the lowest effective dose for the shortest duration.International label, same formulation · Medsafe (New Zealand Medicines and Medical Devices Safety Authority)
• Risk of arterial thrombotic events (myocardial infarction, stroke) and of fluid retention and oedema; caution in hypertension and heart failure.International label, same formulation · Medsafe (New Zealand Medicines and Medical Devices Safety Authority)
• Gastrointestinal bleeding, ulceration and perforation, sometimes fatal, particularly in the elderly.International label, same formulation · Medsafe (New Zealand Medicines and Medical Devices Safety Authority)

• Salicylates and other NSAIDsConcurrent use not recommended because of increased risk of adverse reactions; salicylates lower tenoxicam levels.Medsafe (New Zealand Medicines and Medical Devices Safety Authority)
• Anti-platelet agents and SSRIsIncreased risk of gastrointestinal bleeding.Medsafe (New Zealand Medicines and Medical Devices Safety Authority)
• MethotrexateReduced methotrexate clearance and risk of methotrexate toxicity; use with caution.Medsafe (New Zealand Medicines and Medical Devices Safety Authority)

• Do not use during the first two trimesters unless the expected benefit outweighs the risk; if needed, use the lowest dose for the shortest time. May impair female fertility.International label, same formulation · Medsafe (New Zealand Medicines and Medical Devices Safety Authority)

• Tenoxicam: Inhibits prostaglandin synthesis by inhibiting COX-1 and COX-2 to a similar extent; also inhibits platelet aggregation.